Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADPT NASDAQ:CTMX NASDAQ:ELVN NASDAQ:RARE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$16.90-6.5%$14.17$9.90▼$20.76$2.89B2.151.66 million shs2.16 million shsCTMXCytomX Therapeutics$3.00-5.7%$4.09$1.72▼$8.21$541.19M2.083.32 million shs3.42 million shsELVNEnliven Therapeutics$34.71-2.2%$41.44$14.78▼$48.53$2.16B0.29724,930 shs1.08 million shsRAREUltragenyx Pharmaceutical$21.91-6.0%$23.69$18.29▼$42.37$2.30B0.371.50 million shs1.12 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies+13.07%+19.03%+31.20%+21.75%+81.16%CTMXCytomX Therapeutics-1.24%-14.29%-22.06%-32.05%+26.69%ELVNEnliven Therapeutics-1.50%-12.69%-14.65%+20.55%+59.22%RAREUltragenyx Pharmaceutical+4.02%+0.21%-6.80%+9.69%-36.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$16.90-6.5%$14.17$9.90▼$20.76$2.89B2.151.66 million shs2.16 million shsCTMXCytomX Therapeutics$3.00-5.7%$4.09$1.72▼$8.21$541.19M2.083.32 million shs3.42 million shsELVNEnliven Therapeutics$34.71-2.2%$41.44$14.78▼$48.53$2.16B0.29724,930 shs1.08 million shsRAREUltragenyx Pharmaceutical$21.91-6.0%$23.69$18.29▼$42.37$2.30B0.371.50 million shs1.12 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies+13.07%+19.03%+31.20%+21.75%+81.16%CTMXCytomX Therapeutics-1.24%-14.29%-22.06%-32.05%+26.69%ELVNEnliven Therapeutics-1.50%-12.69%-14.65%+20.55%+59.22%RAREUltragenyx Pharmaceutical+4.02%+0.21%-6.80%+9.69%-36.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies 2.63Moderate Buy$19.5715.81% UpsideCTMXCytomX Therapeutics 2.91Moderate Buy$12.10303.33% UpsideELVNEnliven Therapeutics 2.83Moderate Buy$61.8078.05% UpsideRAREUltragenyx Pharmaceutical 2.82Moderate Buy$59.56171.85% UpsideCurrent Analyst Ratings BreakdownLatest CTMX, ADPT, ELVN, and RARE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026ELVNEnliven Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$45.00 ➝ $62.005/21/2026RAREUltragenyx Pharmaceutical Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$84.00 ➝ $96.005/19/2026CTMXCytomX Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$6.005/19/2026CTMXCytomX Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$6.005/12/2026ADPTAdaptive Biotechnologies Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$21.00 ➝ $18.005/12/2026ELVNEnliven Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$80.005/11/2026CTMXCytomX Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$17.00 ➝ $11.005/11/2026ELVNEnliven Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/8/2026RAREUltragenyx Pharmaceutical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/8/2026ELVNEnliven Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$41.00 ➝ $59.005/8/2026RAREUltragenyx Pharmaceutical GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$52.00 ➝ $43.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$276.98M9.76N/AN/A$1.47 per share11.50CTMXCytomX Therapeutics$76.20M6.70N/AN/A$0.58 per share5.17ELVNEnliven TherapeuticsN/AN/AN/AN/A$7.74 per shareN/ARAREUltragenyx Pharmaceutical$673M3.21N/AN/A($0.83) per share-26.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$59.50M-$0.33N/AN/AN/A-16.82%-40.06%-16.64%8/4/2026 (Estimated)CTMXCytomX Therapeutics-$17.37M-$0.41N/AN/AN/A-166.40%-36.61%-28.02%8/6/2026 (Estimated)ELVNEnliven Therapeutics-$103.69M-$1.67N/AN/AN/AN/A-21.04%-20.41%8/12/2026 (Estimated)RAREUltragenyx Pharmaceutical-$575M-$6.11N/AN/AN/A-91.03%-1,024.42%-45.78%8/4/2026 (Estimated)Latest CTMX, ADPT, ELVN, and RARE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026CTMXCytomX Therapeutics-$0.14-$0.10+$0.04-$0.10$4.68 million$10.26 million5/7/2026Q1 2026ELVNEnliven Therapeutics-$0.44-$0.38+$0.06-$0.38N/AN/A5/5/2026Q1 2026ADPTAdaptive Biotechnologies-$0.16-$0.13+$0.03-$0.13$61.03 million$70.87 million5/5/2026Q1 2026RAREUltragenyx Pharmaceutical-$1.4878-$1.84-$0.3522-$1.84$158.19 million$136.00 million3/16/2026Q4 2025CTMXCytomX Therapeutics-$0.08-$0.22-$0.14-$0.22$7.33 million$0.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/ACTMXCytomX TherapeuticsN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A3.353.22CTMXCytomX TherapeuticsN/A10.3810.38ELVNEnliven TherapeuticsN/A40.3240.32RAREUltragenyx PharmaceuticalN/A2.021.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%CTMXCytomX Therapeutics67.77%ELVNEnliven Therapeutics95.08%RAREUltragenyx Pharmaceutical97.67%Insider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies5.70%CTMXCytomX Therapeutics6.60%ELVNEnliven Therapeutics3.00%RAREUltragenyx Pharmaceutical5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies790160.04 million150.92 millionOptionableCTMXCytomX Therapeutics170170.19 million158.96 millionOptionableELVNEnliven Therapeutics5060.90 million59.08 millionOptionableRAREUltragenyx Pharmaceutical1,37198.49 million93.37 millionOptionableCTMX, ADPT, ELVN, and RARE HeadlinesRecent News About These CompaniesKuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law FirmJune 4 at 4:36 PM | prnewswire.comUltragenyx (RARE) Down 13.6% Since Last Earnings Report: Can It Rebound?June 4 at 12:35 PM | zacks.comUltragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare ConferenceJune 3 at 4:30 PM | globenewswire.comUltragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells $110,601.81 in StockJune 2 at 4:58 AM | insidertrades.comInsider Selling: Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells 4,653 Shares of StockJune 1, 2026 | marketbeat.comKuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law FirmJune 1, 2026 | newsfilecorp.comNKuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law FirmJune 1, 2026 | newsfilecorp.comNWhat to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One YearMay 30, 2026 | finance.yahoo.comJefferies Financial Group Inc. Takes $10.97 Million Position in Ultragenyx Pharmaceutical Inc. $RAREMay 25, 2026 | marketbeat.comBlue Owl Capital Holdings LP Decreases Position in Ultragenyx Pharmaceutical Inc. $RAREMay 25, 2026 | marketbeat.comNorthwestern Mutual Wealth Management Co. Has $4.63 Million Stock Position in Ultragenyx Pharmaceutical Inc. $RAREMay 24, 2026 | marketbeat.comFideuram Intesa Sanpaolo Private Banking S.P.A. Makes New Investment in Ultragenyx Pharmaceutical Inc. $RAREMay 24, 2026 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 24, 2026 | marketbeat.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 22, 2026 | globenewswire.comFideuram Intesa Sanpaolo Private Banking S.P.A. Invests $1.41 Million in Ultragenyx Pharmaceutical Inc. $RAREMay 22, 2026 | marketbeat.comCantor Fitzgerald Issues Positive Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock PriceMay 21, 2026 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Director Shehnaaz Suliman Sells 5,740 SharesMay 19, 2026 | insidertrades.comUltragenyx Pharmaceutical (RARE) Receives a Buy from Wells FargoMay 15, 2026 | theglobeandmail.comUltragenyx Pharmaceutical Sees Unusually Large Options Volume (NASDAQ:RARE)May 15, 2026 | marketbeat.comUltragenyx Pharmaceutical (RARE) Gets a Buy from Piper SandlerMay 15, 2026 | theglobeandmail.comUltragenyx Pharmaceutical (RARE) Receives a Buy from RBC CapitalMay 15, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCTMX, ADPT, ELVN, and RARE Company DescriptionsAdaptive Biotechnologies NASDAQ:ADPT$16.90 -1.18 (-6.53%) Closing price 04:00 PM EasternExtended Trading$17.40 +0.50 (+2.93%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.CytomX Therapeutics NASDAQ:CTMX$3.00 -0.18 (-5.66%) Closing price 04:00 PM EasternExtended Trading$3.03 +0.03 (+1.10%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Enliven Therapeutics NASDAQ:ELVN$34.71 -0.78 (-2.20%) Closing price 04:00 PM EasternExtended Trading$34.74 +0.03 (+0.10%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Ultragenyx Pharmaceutical NASDAQ:RARE$21.91 -1.40 (-6.01%) Closing price 04:00 PM EasternExtended Trading$21.92 +0.00 (+0.02%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
